We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Lung
6008
Poster (digital)
Clinical
Heart substructures delineation in central lung SBRT and cardiac toxicity
Maria Rodriguez Pla , Spain
PO-1239
“Radiotherapy for Thymic Epithelial Tumors: What Is The Optimal Dose? A Systematic Review.”
Antonio Angrisani, Italy
PO-1240
Role of Prognostic Nutritional Index in Postoperative Radiotherapy for Non-Small Cell Lung Cancer
Hye-Jo Ryu, Korea Republic of
PO-1241
Clinical, pathological and dosimetric factors influencing outcomes in NSCLC treated with SABR
Minal Padden-Modi, United Kingdom
PO-1242
SABR TO PRIMARY TUMOR IN OLIGO-M NSCLC PATIENTS: GOOD NEWS FOR A NEW STANDARD OF CARE!
Fabio Arcidiacono , Italy
PO-1243
STEREOTACTIC ABLATIVE RADIOTHERAPY IN LOCALLY-ADVANCED NON-SMALL-CELL LUNG CANCER: A PHASE II TRIAL
Fabio Arcidiacono , Italy
PO-1244
Radiomics features and functional radiosensitivity enhances prediction of acute pulmonary toxicity.
Vincent Bourbonne, France
PO-1245
Lung SBRT after pneumonectomy
Angela Botticella, France
PO-1246
Predictive factors for 90 day mortality in stage III NSCLC patients treated with chemo-radiotherapy
Maarten Lambrecht, Belgium
PO-1247
Efficacy of Concurrent Neoadjuvant Chemoradiotherapy in Patients with LA-Non-small-Cell Lung Cancer
Carlo Greco, Portugal
PO-1248
The impact of COVID-19 pandemic in the lung cancer treatment in a radiotherapy service
Susana Costa, Portugal
PO-1249
Exploring published acute esophagitis models to support improved clinical management in thoracic RT
Maria Thor, USA
PO-1250
Perceived-health status in lung cancer survivors presenting long-term radiotherapy-related fatigue.
Paula Blasco Valls, Spain
PO-1251
Treatment patterns and prognosis in inoperable stage III NSCLC treated with concurrent CRT +/- ICI
Benedikt Flörsch, Germany
PO-1252
Lung metastases from different primary tumors treated with Stereotactic ablative radiotherapy
Jady Vivian Rojas Cordero, Spain
PO-1253
SBRT vs 3D-CRT FOR OLIGOMETASTATIC BONE NSCLC
Giulia Marvaso, Italy
PO-1254
Retrospective analysis of synchronous NSCLC stage IV oligometastatic treated with local treatments
Diane Jornet, France
PO-1255
Multi-domain automated lung segmentation for inflammatory lung disease (ILD) detection
Andrew Hope, Canada
PO-1256
Impact of modern RT in advanced NSCLC: an exploratory real-life investigation from Lombardy
Giulia Corrao, Italy
PO-1257
Patient-reported symptoms in lung cancer survivors after radiotherapy treatment
Antonio Lazo Prados, Spain
PO-1258
Practical results of salvage treatment for regional recurrences after primary SABR for lung cancer
Choongwon Lee, Korea Republic of
PO-1259
Adaptive Radiotherapy in Lung Cancer – Is it Worthwhile??
JAI PRAKASH AGARWAL, India
PO-1260
Is SBRT an effective treatment in metastatic lung cancer with oligoprogressive disease?
Michele Aquilano, Italy
PO-1261
Early response to chemotherapy as predictor of locoregional and distant failure in NSCLC
Marie Tvilum, Denmark
PO-1262
Measurement of tumor hypoxia in patients with non-small cell lung cancer using PET with 18F-FAZA
AVIPSA DAS, Canada
PO-1263
SCORE/SCORE2-OP cardiovascular risk and lung stereotactic body radiation therapy
Maria Rodriguez Pla , Spain
PO-1264
Title: DLCO decrease in a prospective cohort of VMAT-treated lung cancer patients (NCT03931356)
Martin Rehn, France
PO-1265
Evaluation of acute cardiac toxicity in locally advanced lung cancer patients
Maria Cerrolaza, Spain
PO-1266
Pulmonary toxicities after chemoradiation followed by durvalumab for stage III NSCLC: a real setting
Constance Nicolet, France
PO-1267
SABR IN LA-NSCLC ELDERLY PATIENTS UNFIT TO CONCURRENT ChT-RT: FEW FRACTIONS FOR A GREAT OUTCOME!
Fabio Arcidiacono , Italy
PO-1268
SABR in locally-advanced non-small-cell lung cancer elderly patients: little palliation or big cure?
Fabio Arcidiacono , Italy
PO-1269
Reduction of the acute pulmonary toxicity with a VMAT adaptive radiotherapy in lung cancer patients
Vincent Bourbonne, France
PO-1270
REDETERMINATION OF PD-L1 EXPRESSION AFTER CHEMO-RADIATION IN LOCALLY ADVANCED PD-L1 NEGATIVE NSCLC (RECAL TRIAL
Salvatore Cozzi, Italy
PO-1271
SBRT for oligoprogressive/oligorecurrent SCLC: is it worth it?
Antonin Levy, France
PO-1272
Identifying the target: An audit of radiology reports for appropriate use of slice reference numbers
Rachael Wooder, United Kingdom
PO-1273
Is a once-daily RT dose optimal for patients with underlying lung disease in limited-stage SCLC?
Byoung Hyuck Kim, Korea Republic of
PO-1274
Acute toxicity associated to hypofractionation vs. standard fractionation in lung cancer treatment
Macarena M. Teja Ubach, Spain
PO-1275
Re-irradiation in NSCLC High-dose RT: Control, Survival and Toxicity. Single institution experience
Jorge Germain, Spain
PO-1277
Time to local failure and prognosis in lung cancer treated with stereotactic body radiotherapy
Yasushi Hamamoto, Japan
PO-1278
PFS and recurrence patterns after CCRT with durvalumab for stage III and recurrent NSCLC
Noriko Kishi, Japan
PO-1279
Clinical benefits of proton therapy in thymic epithelial tumors using a model-based approach
Stephanie Peeters, The Netherlands
PO-1280
Hypofractionation in locally advanced NSCLC: outcome, toxicity and predictive factors
Davide Franceschini, Italy
PO-1281